BCL-3 and NF-kappaB p50 attenuate lipopolysaccharide-induced inflammatory responses in macrophages. 2004

Jennifer Wessells, and Mark Baer, and Howard A Young, and Estefania Claudio, and Keith Brown, and Ulrich Siebenlist, and Peter F Johnson
Laboratory of Protein Dynamics and Signaling, NCI-Frederick, Frederick, Maryland 21702-1201, USA.

Lipopolysaccharide (LPS) induces expression of tumor necrosis factor alpha (TNFalpha) and other pro-inflammatory cytokines in macrophages. Following its induction, TNFalpha gene transcription is rapidly attenuated, in part due to the accumulation of NF-kappaB p50 homodimers that bind to three kappaB sites in the TNFalpha promoter. Here we have investigated the inhibitory role of BCL-3, an IkappaB-like protein that interacts exclusively with p50 and p52 homodimers. BCL-3 was induced by LPS with delayed kinetics and was associated with p50 in the nucleus. Forced expression of BCL-3 suppressed LPS-induced transcription from the TNFalpha promoter and inhibited two artificial promoters composed of TNFalphakappaB sites that preferentially bind p50 dimers. BCL-3-mediated repression was reversed by trichostatin A and was enhanced by overexpression of HDAC-1, indicating that transcriptional attenuation involves recruitment of histone deacetylase. Analysis of macrophages from p50 and BCL-3 knock-out mice revealed that both transcription factors negatively regulate TNFalpha expression and that BCL-3 inhibits IL-1alpha and IL-1beta. In contrast, induction of the anti-inflammatory cytokine IL-10 was reduced in BCL-3 null macrophages. BCL-3 was not required for the production of p50 homodimers but BCL-3 expression was severely diminished in p50-deficient cells. Together, these findings indicate that p50 and BCL-3 function as anti-inflammatory regulators in macrophages by attenuating transcription of pro-inflammatory cytokines and activating IL-10 expression.

UI MeSH Term Description Entries
D008070 Lipopolysaccharides Lipid-containing polysaccharides which are endotoxins and important group-specific antigens. They are often derived from the cell wall of gram-negative bacteria and induce immunoglobulin secretion. The lipopolysaccharide molecule consists of three parts: LIPID A, core polysaccharide, and O-specific chains (O ANTIGENS). When derived from Escherichia coli, lipopolysaccharides serve as polyclonal B-cell mitogens commonly used in laboratory immunology. (From Dorland, 28th ed) Lipopolysaccharide,Lipoglycans
D008264 Macrophages The relatively long-lived phagocytic cell of mammalian tissues that are derived from blood MONOCYTES. Main types are PERITONEAL MACROPHAGES; ALVEOLAR MACROPHAGES; HISTIOCYTES; KUPFFER CELLS of the liver; and OSTEOCLASTS. They may further differentiate within chronic inflammatory lesions to EPITHELIOID CELLS or may fuse to form FOREIGN BODY GIANT CELLS or LANGHANS GIANT CELLS. (from The Dictionary of Cell Biology, Lackie and Dow, 3rd ed.) Bone Marrow-Derived Macrophages,Monocyte-Derived Macrophages,Macrophage,Macrophages, Monocyte-Derived,Bone Marrow Derived Macrophages,Bone Marrow-Derived Macrophage,Macrophage, Bone Marrow-Derived,Macrophage, Monocyte-Derived,Macrophages, Bone Marrow-Derived,Macrophages, Monocyte Derived,Monocyte Derived Macrophages,Monocyte-Derived Macrophage
D011401 Promoter Regions, Genetic DNA sequences which are recognized (directly or indirectly) and bound by a DNA-dependent RNA polymerase during the initiation of transcription. Highly conserved sequences within the promoter include the Pribnow box in bacteria and the TATA BOX in eukaryotes. rRNA Promoter,Early Promoters, Genetic,Late Promoters, Genetic,Middle Promoters, Genetic,Promoter Regions,Promoter, Genetic,Promotor Regions,Promotor, Genetic,Pseudopromoter, Genetic,Early Promoter, Genetic,Genetic Late Promoter,Genetic Middle Promoters,Genetic Promoter,Genetic Promoter Region,Genetic Promoter Regions,Genetic Promoters,Genetic Promotor,Genetic Promotors,Genetic Pseudopromoter,Genetic Pseudopromoters,Late Promoter, Genetic,Middle Promoter, Genetic,Promoter Region,Promoter Region, Genetic,Promoter, Genetic Early,Promoter, rRNA,Promoters, Genetic,Promoters, Genetic Middle,Promoters, rRNA,Promotor Region,Promotors, Genetic,Pseudopromoters, Genetic,Region, Genetic Promoter,Region, Promoter,Region, Promotor,Regions, Genetic Promoter,Regions, Promoter,Regions, Promotor,rRNA Promoters
D011518 Proto-Oncogene Proteins Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity. Cellular Proto-Oncogene Proteins,c-onc Proteins,Proto Oncogene Proteins, Cellular,Proto-Oncogene Products, Cellular,Cellular Proto Oncogene Proteins,Cellular Proto-Oncogene Products,Proto Oncogene Products, Cellular,Proto Oncogene Proteins,Proto-Oncogene Proteins, Cellular,c onc Proteins
D005786 Gene Expression Regulation Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control (induction or repression) of gene action at the level of transcription or translation. Gene Action Regulation,Regulation of Gene Expression,Expression Regulation, Gene,Regulation, Gene Action,Regulation, Gene Expression
D000081242 B-Cell Lymphoma 3 Protein A member of the I kappa B family, B-cell lymphoma 3-encoded (bcl-3) protein is involved in the regulation of TRANSCRIPTIONAL ACTIVATION of NF-KAPPA B target genes. BCL-3 Protein,BCL3 Protein,Protein c-bcl-3,Proto-Oncogene Protein bcl-3,Proto-Oncogene Proteins c-bcl-3,c-bcl-3 Protein,B Cell Lymphoma 3 Protein,BCL 3 Protein,Protein bcl-3, Proto-Oncogene,Protein c bcl 3,Protein, BCL-3,Protein, BCL3,Proteins c-bcl-3, Proto-Oncogene,Proto Oncogene Protein bcl 3,Proto Oncogene Proteins c bcl 3,bcl-3, Proto-Oncogene Protein,c-bcl-3, Protein,c-bcl-3, Proto-Oncogene Proteins
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014157 Transcription Factors Endogenous substances, usually proteins, which are effective in the initiation, stimulation, or termination of the genetic transcription process. Transcription Factor,Factor, Transcription,Factors, Transcription
D014409 Tumor Necrosis Factor-alpha Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS. Cachectin,TNF-alpha,Tumor Necrosis Factor Ligand Superfamily Member 2,Cachectin-Tumor Necrosis Factor,TNF Superfamily, Member 2,TNFalpha,Tumor Necrosis Factor,Cachectin Tumor Necrosis Factor,Tumor Necrosis Factor alpha
D016328 NF-kappa B Ubiquitous, inducible, nuclear transcriptional activator that binds to enhancer elements in many different cell types and is activated by pathogenic stimuli. The NF-kappa B complex is a heterodimer composed of two DNA-binding subunits: NF-kappa B1 and relA. Immunoglobulin Enhancer-Binding Protein,NF-kappa B Complex,Nuclear Factor kappa B,Transcription Factor NF-kB,kappa B Enhancer Binding Protein,Ig-EBP-1,NF-kB,NF-kappaB,Nuclear Factor-Kappab,Complex, NF-kappa B,Enhancer-Binding Protein, Immunoglobulin,Factor NF-kB, Transcription,Factor-Kappab, Nuclear,Ig EBP 1,Immunoglobulin Enhancer Binding Protein,NF kB,NF kappa B Complex,NF kappaB,NF-kB, Transcription Factor,Nuclear Factor Kappab,Transcription Factor NF kB

Related Publications

Jennifer Wessells, and Mark Baer, and Howard A Young, and Estefania Claudio, and Keith Brown, and Ulrich Siebenlist, and Peter F Johnson
April 2010, Biochemical and biophysical research communications,
Jennifer Wessells, and Mark Baer, and Howard A Young, and Estefania Claudio, and Keith Brown, and Ulrich Siebenlist, and Peter F Johnson
February 2010, Inflammation,
Jennifer Wessells, and Mark Baer, and Howard A Young, and Estefania Claudio, and Keith Brown, and Ulrich Siebenlist, and Peter F Johnson
January 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology,
Jennifer Wessells, and Mark Baer, and Howard A Young, and Estefania Claudio, and Keith Brown, and Ulrich Siebenlist, and Peter F Johnson
July 2010, Cell biology international,
Jennifer Wessells, and Mark Baer, and Howard A Young, and Estefania Claudio, and Keith Brown, and Ulrich Siebenlist, and Peter F Johnson
December 2006, Cancer research,
Jennifer Wessells, and Mark Baer, and Howard A Young, and Estefania Claudio, and Keith Brown, and Ulrich Siebenlist, and Peter F Johnson
September 1999, The EMBO journal,
Jennifer Wessells, and Mark Baer, and Howard A Young, and Estefania Claudio, and Keith Brown, and Ulrich Siebenlist, and Peter F Johnson
February 2016, Pharmaceutical research,
Jennifer Wessells, and Mark Baer, and Howard A Young, and Estefania Claudio, and Keith Brown, and Ulrich Siebenlist, and Peter F Johnson
July 2010, International immunopharmacology,
Jennifer Wessells, and Mark Baer, and Howard A Young, and Estefania Claudio, and Keith Brown, and Ulrich Siebenlist, and Peter F Johnson
August 2015, Human & experimental toxicology,
Jennifer Wessells, and Mark Baer, and Howard A Young, and Estefania Claudio, and Keith Brown, and Ulrich Siebenlist, and Peter F Johnson
April 2020, Immunopharmacology and immunotoxicology,
Copied contents to your clipboard!